Key points are not available for this paper at this time.
The representative SARS-CoV-2 3CL pro inhibitors reported since 2020 and their biological activities and binding models are reviewed, providing new insights into the design and development of more effective 3CL pro inhibitors against SARS-CoV-2.
Chen et al. (Thu,) studied this question.